It seems that it has already dropped a bit but given the fact that it has stopped it's own studyfor Alzheimer's medication due to low enrollment as well as the CEO leaving, there maybe more turbulence ahead.
It has been up about 20% from its low ahead of earnings which I believe they will miss because of decreased utilization of Spiranza which has been very popular until recently.
Finally, it has another Alzheimer's drug bein rapidly reviewed by the FDA but I think there will be an extra high bar given their last approval is still being investigated for impropriety in approval.
any thoughts?
Leave a Reply